For all mankind the bleeding edge4/8/2023 In the months that follow, it will spring back to life. That tells me it’s only a matter of time before capital flows back into the sector again. The biotech sector has been beaten down in the equity markets for about 15 months now due to the policies surrounding the pandemic… but we are still seeing incredible developments like this. It’s also very bullish for CRISPR Therapeutics (CRSP), Vertex Pharmaceuticals (VRTX), and even other companies working on CRISPR-based therapies. So this is an exciting moment in time for the precision medicine industry. They plan to apply for approval either late this year or early 2023. They won’t have to go through a lifetime of blood transfusions as they grow up.Īs a result, CRISPR and Vertex are now in position to be the first companies to get a CRISPR-based therapy approved by the U.S. And it’s great for the affected children who are born with these blood disorders. Thanks to these great results, CRISPR and Vertex are extending their trials to children under the age of 12. The clinicians take cells out of the patient’s body, modify them in a lab using CRISPR, then inject the cells back into the patient. Talk about remarkable results.Īnd here’s the thing – these are one-time treatment options. That means all 75 patients in these two trials have experienced a functional cure or incredible improvements. They have seen an 89% and a 75% reduction in their transfusion volume, respectively. That’s incredible considering they typically needed a transfusion every few months before this treatment.Īnd even the two patients who still needed blood transfusions experienced tremendous benefits. The second is for patients with beta thalassemia.Īnd the latest data is almost unbelievable.Īll 31 of the initial patients in the sickle-cell trial have been free from episodes of severe pain since treatment.Īnd 42 of the 44 blood thalassemia patients have not required any blood transfusions since treatment. The first trial targets sickle-cell disease. Two of our favorite biotech companies, CRISPR Therapeutics and Vertex Pharmaceuticals, just released updated results from joint clinical trials of their lead CRISPR therapy. You can sign up in seconds by going right here. If you haven’t yet RSVP’d, please don’t wait. ET, I’ll go over how these “mandated” investments work… and how we can all profit from them even amid the current volatility.Īnd I’d like to invite all my readers to attend. That’s why tonight, I’ll be presenting all the facts at my “Washington D.C.’s Mandated Money” event. In other words, they want to keep these investments all to themselves. There’s even legislation in the works to restrict these investment vehicles to accredited investors. Yet despite making big money on these deals, the elites are busy calling them “complicated” and even “dangerous” in the press. And that’s invaluable in this kind of market environment. In fact, these investments are the only ones where our money is contractually protected. And that’s not counting any long-term gains that result from these deals. That’s because right now, investors are “mandated” to make up to $2,300 upfront. That’s why I want to bring awareness about one particular kind of investment… one that billionaires, elected officials, and hedge funds are currently using to profit. We’ve all felt the effects of the market shift to bearish sentiment. I know market volatility has been at the forefront of investors’ minds. Microsoft is shooting itself in the foot….TSMC’s semiconductor road map has good news….
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |